Insider Cluster (2 insiders) ·Filed Aug 5, 2026

VCEL

Vericel Corp
NEUTRAL
Impact 2/10
Horizondays Processed1mo ago
Insider cluster: 2 insiders, $542K total
Actionable Insight • Neutral

These insider sales are immaterial in size and likely routine. The stronger signal is the recent Q2 earnings beat and raised guidance, which are bullish. No follow-up action required; watch for any meaningful insider buying (e.g., >$1M) as a stronger conviction signal.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d
VCEL ▼ -9.85% at T+20d
NEUTRAL call ✗ call lost -9.85% · α vs SPY -9.25% · entry $45.36 → $40.89
Next anchor: T+60d in 26d
Latest observation: T+38 -17.92% FF3 residual α
Entry anchored
Aug 4, 06:29 PM ET
via 1-min bar
T+1d
-1.34%
call -1.34% · α -1.19%
$44.75
settled 8w ago
T+5d
-1.39%
call -1.39% · α -1.74%
$44.73
settled 7w ago
T+20d
-9.85%
call -9.85% · α -9.25%
$40.89
settled 4w ago
T+60d
—
call — · α —
—
in 26d

Price Chart

Loading chart...

Executive Summary

Two Vericel insiders sold a combined $541,400 in shares over a 7-day window, with the COO's sale being a same-day exercise-and-sell of derivative shares. The total value is only 0.024% of market cap — trivial and routine. The cluster follows a strong Q2 earnings beat and raised guidance, so these sales likely reflect liquidity or tax planning rather than negative sentiment.

Key Financial Metrics

Direction
selling
Total Value
$541.4K
Insiders
2

Key Facts

  • COO Michael Halpin sold 10,000 shares at $46.84 on 8/3/2026, netting $468,400, after exercising derivative shares at $0 and $16.66 (non-cash combined value).
  • Principal Accounting Officer Jonathan Siegal sold 1,500 shares at $48.90 on 7/30/2026, total $73,000.
  • Total insider sales of $541,400 represent 0.024% of VCEL's $2.3B market cap.
  • Cluster occurred 7 days after Vericel reported Q2 2026 revenue of $77.5M (+22% YoY), beat consensus, and raised full-year 2026 revenue guidance to $330-340M.

Financial Impact

Total insider sales of $541,400, trivial relative to $2.3B market cap

dilutioninsider ownership

Risk Factors

  • Further insider selling above 0.5% of market cap could shift sentiment.
  • No risk from this cluster given its trivial size and routine nature.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-VCEL-1786004445585
12 reports for VCEL
Performance horizon
50% Hit rate 2 of 4 directional calls best @ T+60▲ +31.08%May 7, 2026
Filters
Rows
Reports for VCEL — sortable, filterable
TypeNow
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$45.36 $40.89▼ −9.85%▼ −9.25%$39.99 (−11.83%)
Jul 30, 2026
9w ago
8-K
BULLISH ★ 6/10
$47.61 $41.18▼ −13.51%▼ −17.47%$39.99 (−15.99%)
Jul 16, 2026
11w ago
Press Release
NEUTRAL ★ 2/10
$47.81 $44.54▼ −6.84%▼ −10.46%$39.99 (−16.35%)
Jun 30, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$45.15 $46.62▲ +3.26%▲ +5.44%$39.99 (−11.42%)
Jun 2, 2026
17w ago
144
NEUTRAL ★ 2/10
$34.45 $45.15▲ +31.06%▲ +32.62%$39.99 (+16.10%)
May 15, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$34.87 $38.46▲ +10.30%▲ +8.71%$39.99 (+14.70%)
May 7, 2026
21w ago
8-K
BULLISH ★ 7/10
$35.13 $34.74▼ −1.11%▼ −4.25%$39.99 (+13.85%)
May 7, 2026
21w ago
Press Release
BULLISH ★ 8/10
$35.13 $34.74▼ −1.11%▼ −4.25%$39.99 (+13.85%)
Apr 23, 2026
23w ago
Press Release
NEUTRAL ★ 3/10
$34.40 $35.40▲ +2.91%▼ −1.73%$39.99 (+16.26%)
Mar 19, 2026
28w ago
DEFA14A
NEUTRAL ★ 3/10
$32.74 $35.68▲ +8.98%▲ +1.36%$39.99 (+22.16%)
Showing 10 of 12

US Market Status

Market Open — Closes in 2h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 6, 2026